Hadassah

FDA Grants Approval for US Clinical Trials of Hadassah-Developed Technology to Treat Fatty Liver Disease

Wednesday, Dec 17 2014

A new drug technology, developed at the Hadassah Medical Organization to treat fatty liver disease--a condition with no approved effective drug treatment--was given the go-ahead by the United States Food and Drug Administration (FDA) for a Phase 2 multi-center clinical trial in the US.

In its severe form (called nonalcoholic steatohepatitis-NASH), fatty liver disease can lead to cirrhosis and liver cancer. Current estimates reveal that at least five percent of the Western world’s population suffers from the disease. The majority of these patients also have diabetes, high blood lipids, and obesity.

The new technology was developed by Prof. Yaron Ilan, Director, Department of Internal Medicine and former president of the Israel Liver Association, and his team in Hadassah’s Liver Unit. Based on feeding natural antibodies against intestinal bacteria associated with fatty liver disease, the treatment reduces inflammation by directly affecting the activity level of regulatory T cells in the liver and fat tissues. “The new drug is based on a novel discovery that bacteria in our gut are relevant for the induction of inflammation in our body, which is associated with liver disease, diabetes, and obesity” said Prof. Ilan. “The new therapy is safe and has no side effect, and we hope the results of the phase II trial will enable us to move forward with its development as a treatment for diabetes and fatty liver disease”.

Hadasit, Hadassah’s technology transfer arm, and Immuron, an Australian biopharmaceutical company, worked together to develop the product. The collaborative effort combines Hadassah’s oral immune modulation approach with antibodies produced by Immuron.

The multi-center clinical trial will involve 120 patients in several leading medical centers in the US and Australia. The cohort will receive the treatment for six months, while monitored for the state of their liver disease, diabetes, and lipid profile.

Clinical trials were already conducted at Hadassah, which confirmed the safety and efficacy of the treatment.

Read about the 2009 discovery of treatment for fatty liver disease

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Monday, Oct 16 2017

Organ Donation from Cyprus Saves Young Woman in Israel

Thanks to an agreement of cooperation between the health ministries of Israel and Cyprus, a liver donated by a woman from Nicosia saved a young woman’s life in Israel.

READ MORE ›
alt_text

Monday, Oct 9 2017

Honoring a Hadassah Leader's Legacy with Increased Breast Cancer Programming

Jill Stenzler-Engelman devoted 15 years to Hadassah's Check It Out® breast cancer awareness program in St. Petersburg, Florida. She taught breast self-exam and early detection at high schools, jails, and more. Her husband, Dr. Greg Engelman, said, “Jill loved to teach and loved educating young adults and adults on being proactive about their health.” Sadly, after a courageous 10-year battle, Jill died of ovarian cancer at age 53.

READ MORE ›
alt_text

Monday, Oct 9 2017

Dr. Tamar Elram Announcement

The administration of Hadassah Medical Organization is pleased to announce the selection of Dr. Tamar Elram as the new Director of the Hadassah Mount Scopus Hospital.

READ MORE ›
alt_text

Wednesday, Oct 4 2017

Hadassah Medical Organization Sends Top Adolescent Trauma Expert to Mexico to Aid Earthquake-Ravaged Victims

Hadassah has sent one of the world’s top experts on adolescent Post Traumatic Stress Disorder Syndrome (PTSD) to Mexico City.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More